- Global Pharma News & Resources

Global Atrial Fibrillation Market Research Report 2022: Treatment Types and End-User Facilities - Forecast to 2027 -

DUBLIN--(BUSINESS WIRE)--The "Global Atrial Fibrillation Market - Treatment Types and End-User Facilities" report has been added to's offering.

The report reviews, analyzes and projects the global Atrial Fibrillation market for the period 2018-2027 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2022 through 2027 with a special focus on y-o-y growth for 2019, 2020 and 2021.

Atrial Fibrillation (AF) is the most common arrhythmia, which can lead to stroke, peripheral embolization, heart failure and other unfavorable outcomes. While the incidence of AF among the general population has been found to be at about 2.3%-3.4%, this registers a significant increase in patients with pulmonary disease, critical illness or systemic inflammatory response syndrome, with devastating clinical impact.

A number of recent epidemiological studies have established a greater risk of AF and new-onset AF among patients with COVID-19, though the results have been quite inconsistent. The literature available thus far has indicated that AF or new-onset AF can have a substantial association with the worst outcomes, viz., mortality, in patients with COVID-19.

Apart from the recent development of COVID-19 and its effect on AF, other factors that increase the risk of this condition include growing worldwide prevalence of obesity and heart diseases. The rise in the number of AF cases is fueling the market for treating this disease, though at the same time posing a crushing burden on the economies of several countries because of the high treatment cost involved.

Research Findings & Coverage

  • Global Atrial Fibrillation market is analyzed in this report with respect to treatment type/sub-type, end-user facilities
  • The study exclusively analyzes the market size of each treatment type/sub-type and end-user facility of Atrial Fibrillation by all major geographic regions/countries
  • Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
  • Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
  • Thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
  • Revolutionary Catheter Ablation Technologies for AF Take Centerstage
  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
  • Major companies profiled - 19
  • The industry guide includes the contact details for 70 companies

Product Outline

The report analyzes the market for the following key treatment types/sub-types of Atrial Fibrillation:

  • Non-Pharmacological Treatment
    • Catheter Ablation
    • Electric Cardioversion
    • High Intensity Focused Ultrasound (HIFU)
    • Maze Surgery
    • Other Ablation Treatments
  • Pharmacological Treatment
    • Blood Thinners
    • Heart Rate Drugs
    • Heart Rhythm Drugs

End-User Facilities of Atrial Fibrillation analyzed in this study comprise the following:

  • Ambulatory Surgical Centers
  • Cardiac Centers
  • Hospitals


  • Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
  • Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLXT LAAC Device
  • Boston Scientific Closes Acquisition of Baylis Medical Company Inc.
  • Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition
  • Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
  • Acutus Medical's Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium
  • Medtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System
  • Medtronic to Acquire Affera
  • Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
  • Acutus Medical Initiates CE Mark Study for Focal Pulsed Field Ablation Therapy to Treat Atrial Fibrillation
  • Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke
  • Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
  • Biosense Webster Announces Completion of Atrial Fibrillation Cases Using Novel HELIOSTART Balloon Ablation Catheter
  • New Data & Innovations: Heart Rhythm 2021
  • BIOTRONIK Expands Range of Peripheral Introducer Sheaths
  • CardioFocus-Announces-Agreement-to-Acquire-Intellectual-Property-Press-Release.pdf
  • Late-Breaking Data Shows Abbott's AmplatzerT AmuletT Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman? Device for People With Atrial Fibrillation at Risk of Stroke
  • Abbott's AmplatzerT AmuletT Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
  • AcQMap 8, Acutus Medical's Innovative Suite of Software Upgrades, Receives FDA Clearance and CE Mark
  • Real-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless Pacemaker
  • Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
  • Abbott Receives European And Canadian Approval For AmplatzerT Steerable Delivery Sheath To Optimize Left Atrial Appendage Closure Procedures For People At Risk Of Stroke
  • Medtronic Receives FDA Expanded Approval for Arctic FrontT Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation
  • Abbott Introduces Jot DxT Insertable Cardiac Monitor, Designed To Reduce Data Burden And Improve Accurate Diagnosis Of Difficult-To-Detect Abnormal Heart Rhythms
  • AliveCor and Acutus Medical Partner to Evaluate Management and Treatment of Cardiac Arrhythmias
  • New Data & Innovations: Heart Rhythm 2021
  • BIOTRONIK's Cardiac Monitor Receives Prestigious Award
  • Late-Breaking Trial Data at TVT Demonstrate Sustained Safety and Performance of WATCHMAN FLXT Left Atrial Appendage Closure Device
  • CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021
  • CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan
  • Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring
  • CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China
  • GE Healthcare and the American College of Cardiology Join Forces to Advance AI in Cardiac Care
  • Medtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes
  • Siemens Healthineers Receives CE Mark for the ACUSON AcuNav Volume ICE Catheter
  • Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
  • Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate FORCE Sensing Ablation System
  • Japan Lifeline Finalizes Supply Agreement for Pulsed Electric Field Ablation Catheter for U.S. Market
  • Acutus Medical Announces FDA Clearance of AcQCrossT, a Full Suite of Universal Transseptal Crossing Devices
  • Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate FORCE Sensing Ablation System
  • AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
  • Acutus Medical Receives Vizient Innovative Technology Contract
  • Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
  • CardioFocus Announces Expanded Partnership With Japan Lifeline
  • CardioFocus Announces Expanded Distribution Partnership With MicroPortT CRM To Include Spain And Portugal
  • Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation
  • Acutus Medical Announces CE Mark and European Launch of AcQCrossT Transseptal System, a Fully Integrated Family of Transseptal Crossing Products
  • CardioFocus Announces 10,000 Patients Treated Worldwide
  • First Clinical Implantation of MicroPort Left.
  • Abbott Introduces Next-Generation 3d Cardiac Mapping Platform In Europe And Australia
  • The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy
  • Acutus Medical Launches AcQBlate Force Sensing Ablation System in Europe
  • Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
  • Acutus Medical Announces FDA Clearance of Second-Generation AcQMap 3D Imaging & Mapping Catheter
  • Acutus Medical Announces Pulsed Field Ablation Program and Initial Pre-Clinical Results
  • Medtronic Gains FDA Clearance, CE Mark for LINQ IIT Insertable Cardiac Monitor (ICM)
  • Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
  • Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support
  • Medtronic MicraT AV Receives CE Mark
  • New Alliance Maps the Way in Electrophysiology
  • CardioFocus Announces US FDA Approval of HeartLight X3 System for the Treatment of Atrial Fibrillation
  • GE Healthcare and Preventice Solutions Collaborate to Connect the Heart, the Hospital and the Home Seamlessly
  • Bristol Myers Squibb - The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis


  • Artificial Intelligence Comes to the Fore in Diagnosing and Managing Arrythmias
  • Digital Health Technologies Take a Lead in Screening for Atrial Fibrillation (AF)
  • thumb ECGs Playing a Greater Role Atrial Fibrillation Detection
  • Atrial Fibrillation Treated Successfully through Pulsed Field Ablation
  • Revolutionary Catheter Ablation Technologies for AF Take Centerstage



Major Market Players

  • Abbott Laboratories (United States)
  • Acutus Medical, Inc. (United States)
  • Atricure, Inc. (United States)
  • Biosense Webster, Inc. (United States)
  • Boston Scientific Corporation (United States)
  • Bristol-Myers Squibb Co. (United States)
  • Cardiofocus, Inc. (United States)
  • GE Healthcare (United States)
  • Pfizer Inc. (United States)
  • Siemens Medical Solutions USA, Inc. (United States)


Major Market Players

  • Acesion Pharma (Denmark)
  • Afreeze GmbH (Austria)
  • Biotronik SE & Co. Kg (Germany)
  • Boehringer Ingelheim International GmbH (Germany)
  • Medtronic PLC (Ireland)
  • Osypka AG (Germany)


Major Market Players

  • Cathrx Ltd (Australia)
  • Japan Lifeline Co. (Japan)
  • Shanghai Microport Medical (Group) Co Ltd (China)

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Jun-2022